VRDN Q4 2022 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

VRDNViridian Therapeutics, Inc.

$3B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$105,000-50.9% YoY

Gross Profit

-$39M-37344.8% margin

Operating Income

-$49M-46729.5% margin

Net Income

-$46M-43604.8% margin

EPS (Diluted)

$-1.05

QoQ Revenue Growth

-91.2%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$435M

Total Liabilities

$40M

Stockholders' Equity

$395M

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$105,000	$214,000	-50.9%
Gross Profit	-$39M	-$22M	-76.8%
Operating Income	-$49M	-$29M	-68.7%
Net Income	-$46M	-$29M	-58.2%

Revenue Segments

Collaboration Revenue

$100,000100%